Abstract
Tumor cells contain a variety of antigens, including tumor associated antigens. The tumor associated antigens can be clinically useful as markers for detection of cancer and some may also mediate host resistance against tumor growth. Much emphasis has been placed on the detection of circulating tumor associated markers, with radioimmunoassays for carcinoembryonic antigen (CEA) being extensively utilized. At present, CEA does not appear to be promising for initial detection of cancer, but may find an important place in the determination of prognosis and early detection of recurrent disease. Many cancer patients have depressed immunologic competence, yet they frequently have cell-mediated immunity against tumor associated antigens. Several different immunotherapeutic strategies have been developed, to either augment the immunologic responsiveness of the patient or to specifically increase the immune reactivity against tumor associated transplantation antigens.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
